Work

Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma

Year: 2026

Type: article

Source: Blood Neoplasia

DOI: 10.1016/j.bneo.2026.100287

Authors: Max J. Gordon, Logan Cook, Milos D. Miljkovic, Rahul Lakhotia, Christopher Melani, Mark Roschewski, Jagan Muppidi, Irini Sereti, Louis M. Staudt, Wyndham H. Wilson, Samuel Ng, Joseph Rocco

Institutions: National Cancer Institute, Center for Cancer Research, National Institutes of Health, National Institute of Allergy and Infectious Diseases

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

Funders: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute

OpenAlex ID: W7202398635

FWCI:

Cites:

Cited by:

Related to: